Investor updates Keyword Search Clear 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Published on: 22 December 2016 Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study more Published on: 21 December 2016 Positive Phase III results for Roche’s investigational medicine OCREVUS® (ocrelizumab) published in New England Journal of Medicine more Published on: 20 December 2016 FDA extends review of application for OCREVUS™ (ocrelizumab) more Published on: 16 December 2016 CHMP recommends EU conditional approval of Roche’s Alecensa (alectinib) for people with previously treated ALK-positive NSCLC more Published on: 8 December 2016 Roche announces European approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia more Published on: 7 December 2016 Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer more Published on: 5 December 2016 Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan more Published on: 5 December 2016 Changes in Roche Board of Directors more Published on: 22 November 2016 Reminder: Invitation to Roche Analyst Event at ASH 2016 more Published on: 15 November 2016 Roche launches imCORE, a global network of cancer immunotherapy centers of excellence more Published on: 12 November 2016 Phase III GiACTA study shows Roche’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis more Published on: 7 November 2016 Roche announces initiation of two phase III pivotal trials in melanoma based on results of studies combining targeted and immunotherapy treatment approaches; early data presented at the International Congress of the Society for Melanoma Research more Published on: 3 November 2016 Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting more Published on: 2 November 2016 Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting more Published on: 31 October 2016 Invitation to Roche Analyst Event at ASH 2016 more Published on: 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 more Published on: 19 October 2016 FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer more Published on: 17 October 2016 FDA approves Lucentis (ranibizumab injection) prefilled syringe more Published on: 14 October 2016 Roche announces CHMP recommendation for EU approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia more Published on: 13 October 2016 Reminder: Invitation to Roche’s 9 Months Sales 2016 Conference Call more Published on: 11 October 2016 FDA grants priority review to Lucentis (ranibizumab injection) supplemental biologics license application for myopic choroidal neovascularization more Published on: 9 October 2016 Roche’s TECENTRIQ (atezolizumab) shows significant survival advantage compared to chemotherapy regardless of PD-L1 status in a specific type of lung cancer in Phase III study more Published on: 5 October 2016 FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis more Published on: 4 October 2016 Save the date: Roche Analyst Event at ASH 2016 more Published on: 4 October 2016 US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC more Published on: 3 October 2016 First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress more Published on: 22 September 2016 Invitation to Roche's Third Quarter Sales 2016 Conference Call more Published on: 14 September 2016 Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis more Published on: 8 September 2016 Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running more Published on: 1 September 2016 Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy more Published on: 26 August 2016 Anti-Cancer Agent “Xeloda®”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer” more Published on: 23 August 2016 Roche launches innovative Accu-Chek Guide blood glucose monitoring system, which makes every step of testing easy more Published on: 28 July 2016 Roche’s emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A more Published on: 27 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 more Published on: 21 July 2016 Roche delivers continued growth in the first half of 2016 more Published on: 19 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 more Published on: 18 July 2016 Roche provides update on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma more Published on: 14 July 2016 Reminder: Invitation to Roche's Half Year Results 2016 more Published on: 5 July 2016 Roche Analyst Event on Diagnostics Division at AACC 2016 more Published on: 28 June 2016 Roche's marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA more Published on: 23 June 2016 Invitation to Roche's Half Year Results 2016 more Published on: 20 June 2016 Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing more Published on: 16 June 2016 Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma more Published on: 8 June 2016 Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer more Published on: 7 June 2016 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2016 more Published on: 6 June 2016 Phase III study shows Roche's Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) more Published on: 5 June 2016 Roche’s cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer more Published on: 4 June 2016 Roche showcases three distinct combinations for cancer immunotherapy treatment across a broad range of cancers more Published on: 4 June 2016 Roche's Tecentriq® (atezolizumab) shows increasing overall survival benefit in updated clinical data analysis for people with specific type of advanced lung cancer more Published on: 31 May 2016 Roche's subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia more Published on: 30 May 2016 First PT/INR home self-testing device with Bluetooth technology enabling remote care programmes for anticoagulated patients more Published on: 27 May 2016 Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma more Published on: 26 May 2016 Reminder: Invitation to Roche Analyst Event at ASCO 2016 more Published on: 24 May 2016 Chugai announcement: Avastin approved for additional indication of advanced or recurrent cervical cancer more Published on: 19 May 2016 Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer more Published on: 19 May 2016 FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer more Published on: 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 29 April 2016 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma more Published on: 29 April 2016 CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer more Published on: 27 April 2016 Invitation to Roche Analyst Event at ASCO 2016 more Published on: 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 more Published on: 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms of multiple sclerosis more Published on: 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia more Published on: 11 April 2016 Reminder: Invitation to Roche's First Quarter Sales 2016 Conference Call more Published on: 11 April 2016 FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer more Published on: 31 March 2016 Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol more Published on: 21 March 2016 Invitation to Roche's First Quarter Sales 2016 Conference Call more Published on: 15 March 2016 FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer more Published on: 1 March 2016 Roche Annual General Meeting 2016 more Published on: 29 February 2016 FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma more Published on: 29 February 2016 Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma more Published on: 26 February 2016 Save the date: Roche Analyst Event at ASCO 2016 more Published on: 17 February 2016 U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis more Published on: 10 February 2016 Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit more Published on: 28 January 2016 Changes to the Roche Corporate Executive Committee more Published on: 28 January 2016 Roche reports strong results in 2015 more Published on: 20 January 2016 FDA grants breakthrough therapy designation for investigational medicine venetoclax in combination with MabThera/Rituxan in relapsed or refractory chronic lymphocytic leukaemia more Published on: 15 January 2016 Reminder: Invitation to Roche's Full Year Results 2015 more Published on: 12 January 2016 FDA grants priority review for venetoclax new drug application more Published on: 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer more Published on: 4 January 2016 Invitation to Roche's Full Year Results 2015 more
Published on: 22 December 2016 Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study more
Published on: 21 December 2016 Positive Phase III results for Roche’s investigational medicine OCREVUS® (ocrelizumab) published in New England Journal of Medicine more
Published on: 16 December 2016 CHMP recommends EU conditional approval of Roche’s Alecensa (alectinib) for people with previously treated ALK-positive NSCLC more
Published on: 8 December 2016 Roche announces European approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia more
Published on: 7 December 2016 Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer more
Published on: 5 December 2016 Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan more
Published on: 15 November 2016 Roche launches imCORE, a global network of cancer immunotherapy centers of excellence more
Published on: 12 November 2016 Phase III GiACTA study shows Roche’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis more
Published on: 7 November 2016 Roche announces initiation of two phase III pivotal trials in melanoma based on results of studies combining targeted and immunotherapy treatment approaches; early data presented at the International Congress of the Society for Melanoma Research more
Published on: 3 November 2016 Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting more
Published on: 2 November 2016 Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting more
Published on: 19 October 2016 FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer more
Published on: 14 October 2016 Roche announces CHMP recommendation for EU approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia more
Published on: 13 October 2016 Reminder: Invitation to Roche’s 9 Months Sales 2016 Conference Call more
Published on: 11 October 2016 FDA grants priority review to Lucentis (ranibizumab injection) supplemental biologics license application for myopic choroidal neovascularization more
Published on: 9 October 2016 Roche’s TECENTRIQ (atezolizumab) shows significant survival advantage compared to chemotherapy regardless of PD-L1 status in a specific type of lung cancer in Phase III study more
Published on: 5 October 2016 FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis more
Published on: 4 October 2016 US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC more
Published on: 3 October 2016 First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress more
Published on: 14 September 2016 Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis more
Published on: 8 September 2016 Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running more
Published on: 1 September 2016 Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy more
Published on: 26 August 2016 Anti-Cancer Agent “Xeloda®”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer” more
Published on: 23 August 2016 Roche launches innovative Accu-Chek Guide blood glucose monitoring system, which makes every step of testing easy more
Published on: 28 July 2016 Roche’s emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A more
Published on: 27 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 more
Published on: 19 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 more
Published on: 18 July 2016 Roche provides update on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma more
Published on: 28 June 2016 Roche's marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA more
Published on: 20 June 2016 Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing more
Published on: 16 June 2016 Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma more
Published on: 8 June 2016 Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer more
Published on: 7 June 2016 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2016 more
Published on: 6 June 2016 Phase III study shows Roche's Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) more
Published on: 5 June 2016 Roche’s cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer more
Published on: 4 June 2016 Roche showcases three distinct combinations for cancer immunotherapy treatment across a broad range of cancers more
Published on: 4 June 2016 Roche's Tecentriq® (atezolizumab) shows increasing overall survival benefit in updated clinical data analysis for people with specific type of advanced lung cancer more
Published on: 31 May 2016 Roche's subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia more
Published on: 30 May 2016 First PT/INR home self-testing device with Bluetooth technology enabling remote care programmes for anticoagulated patients more
Published on: 27 May 2016 Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma more
Published on: 24 May 2016 Chugai announcement: Avastin approved for additional indication of advanced or recurrent cervical cancer more
Published on: 19 May 2016 Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer more
Published on: 19 May 2016 FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer more
Published on: 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 29 April 2016 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma more
Published on: 29 April 2016 CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer more
Published on: 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms of multiple sclerosis more
Published on: 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia more
Published on: 11 April 2016 Reminder: Invitation to Roche's First Quarter Sales 2016 Conference Call more
Published on: 11 April 2016 FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer more
Published on: 31 March 2016 Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol more
Published on: 15 March 2016 FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer more
Published on: 29 February 2016 FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma more
Published on: 29 February 2016 Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma more
Published on: 17 February 2016 U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis more
Published on: 10 February 2016 Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit more
Published on: 20 January 2016 FDA grants breakthrough therapy designation for investigational medicine venetoclax in combination with MabThera/Rituxan in relapsed or refractory chronic lymphocytic leukaemia more
Published on: 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer more